
This is one company that probably won't get a limp reception from the market.
Brisbane-based LTR Pharma on Friday opened its $7 million initial public offering to fund its planned launch of a fast-acting treatment for erectile dysfunction.

This is one company that probably won't get a limp reception from the market.
Brisbane-based LTR Pharma on Friday opened its $7 million initial public offering to fund its planned launch of a fast-acting treatment for erectile dysfunction.